farnesol and Carcinoma, Non-Small Cell Lung

farnesol has been researched along with Carcinoma, Non-Small Cell Lung in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ahn, KS; Alharbi, SA; Chinnathambi, A; Lee, JH; Sethi, G; Shair, OHM	1
Biran, A; Brownstein, M; Haklai, R; Kloog, Y	1
Azzoli, CG; Ginsberg, MS; Johnson, ML; Kris, MG; Krug, LM; Medina, C; Miller, VA; Pao, W; Pietanza, MC; Riely, GJ; Rizvi, NA	1

Trials

1 trial(s) available for farnesol and Carcinoma, Non-Small Cell Lung

Article	Year
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:8 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Farnesol; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salicylates; Survival Rate; Treatment Outcome	2011

Article

Year

A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:8

Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Farnesol; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salicylates; Survival Rate; Treatment Outcome

2011

Other Studies

2 other study(ies) available for farnesol and Carcinoma, Non-Small Cell Lung

Article	Year
Farnesol abrogates epithelial to mesenchymal transition process through regulating Akt/mTOR pathway. Pharmacological research, 2019, Volume: 150 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Farnesol; Female; Humans; Lung Neoplasms; Mice, Nude; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Wound Healing	2019
Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. International journal of cancer, 2011, Feb-01, Volume: 128, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinases; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Down-Regulation; Farnesol; Flow Cytometry; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Salicylates; Survivin; Valproic Acid	2011

Article

Year

Farnesol abrogates epithelial to mesenchymal transition process through regulating Akt/mTOR pathway.

Pharmacological research, 2019, Volume: 150

Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Farnesol; Female; Humans; Lung Neoplasms; Mice, Nude; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Wound Healing

2019

Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy.

International journal of cancer, 2011, Feb-01, Volume: 128, Issue:3

Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinases; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Down-Regulation; Farnesol; Flow Cytometry; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Salicylates; Survivin; Valproic Acid

2011